Where can I buy sotorasib? What are the purchasing channels?

Sotorasib is a targeted therapy specifically designed to treat advanced non-small cell lung cancer (NSCLC) with KRAS G12C mutations. KRAS G12CMutation is a common cancer driver gene mutation, which is particularly widespread in non-small cell lung cancer, posing challenges to patient treatment.

The original drug of sotorasibu has not yet been launched in China, so patients cannot purchase it domestically and need to purchase sotorasibu through overseas channels. The price of the original version of sotorasibu in Hong Kong, China, with the specifications of 120mg*240 tablets, is around 8 million, and the price of the European version of the original drug with the same specifications is around 4 million, which is relatively expensive. The cheaper ones are the generic drugs marketed abroad. For example, the price of generic drugs in Laos and Bangladesh is around two to three thousand yuan. The price is relatively cheap, and the ingredients of foreign generic drugs are basically the same as the original drugs.

What is unique about this drug is its ability to precisely intervene in the KRAS G12C mutation, which causes abnormal cell signaling pathway activity, thereby promoting uncontrolled growth of cancer cells. By inhibiting this abnormal signaling, sotoracib blocks the proliferation and spread of tumor cells, thereby providing a new treatment option for patients.

The development of this drug marks the overcoming of the KRAS G12C mutation that has long been considered difficult to treat, providing new hope for lung cancer patients. Compared with traditional cancer treatments, the targeting nature of sotoraxib makes it more precise and reduces damage to healthy cells, thus reducing the adverse effects of treatment.

However, it should be emphasized that sotorasiib is not suitable for all patients with non-small cell lung cancer, but is limited to individuals carrying theKRAS G12C mutation. Before using sotorasiib, doctors typically perform genetic testing to determine if a patient qualifies for the drug.